PSMD1 and COVID-19: In this study cohort of NSCLC patients, UFT did not affect the anti-S1 antibody titers after COVID-19 vaccination, temporary discontinuation of UFT therapy did not affect the anti-S1 antibody titers after COVID-19 vaccination, and no severe adverse events ( ≥ Grade 3 in CTCAE v5.0) occurred.